

The vascular glycocalyx is not a mechanosensor in conduit arteries in the anesthetized pig

Therese Ruane-O'Hora¹, Ahmad Ahmeda² and Farouk Markos¹

¹ Department of Physiology, School of Medicine, University College Cork, Cork, Ireland

² College of Medicine, QU Health, Qatar University, Doha, Qatar

ABSTRACT

Background: The role of the glycocalyx as the endothelial sensor of an increase in blood flow was assessed in the iliac artery in vivo.

Methods: Acetylcholine-induced flow mediated dilation was evaluated before and after vascular glycocalyx disruption. This was accomplished by exposing the iliac lumen to the chemotactic agent fMLP (1 μM ; $n = 6$ pigs), concomitant heparinase III (100 mU ml^{-1}) and hyaluronidase (14 mg ml^{-1}) ($n = 4$), and neuraminidase (140 mU ml^{-1} ; $n = 5$), for 20 min in separate iliac artery preparations. Only one lumen intervention per iliac was conducted.

Results: For the heparinase III + hyaluronidase experiment, the iliac diameter increased by an average of 0.54 ± 0.11 mm before and 0.45 ± 0.03 mm after the enzymes ($P = 0.42$; paired Student's t test). The iliac diameter increased by 0.31 ± 0.02 mm before and 0.29 ± 0.07 mm after fMLP exposure ($P = 0.7$) and the diameter increased by 0.54 ± 0.11 mm before and 0.54 ± 0.09 mm after neuraminidase exposure ($P = 0.98$). In all cases, the shear stress changes before and after lumen exposure were not significantly different to each other.

Conclusion: There was no significant reduction in flow mediated dilation of the iliac in response to any of the interventions conducted. Therefore, the vascular endothelial glycocalyx as whole is not required for flow mediated dilation in conduit arteries in the intact animal.

Submitted 11 December 2019

Accepted 10 February 2020

Published 2 March 2020

Corresponding author

Farouk Markos, f.markos@ucc.ie

Academic editor

Marek Radomski

Additional Information and
Declarations can be found on
page 7

DOI 10.7717/peerj.8725

© Copyright

2020 Ruane-O'Hora et al.

Distributed under

Creative Commons CC-BY 4.0

OPEN ACCESS

Subjects Veterinary Medicine, Anatomy and Physiology, Pharmacology

Keywords Hyaluronic acid, Glycocalyx, Flow mediated dilation, fMLP, Neuraminidase, Heparan sulfate

INTRODUCTION

A recently published in vivo study has shown that individual removal of heparan sulfate and hyaluronan components the glycocalyx lining endothelial cells on the iliac did not significantly reduce vessel dilation in response to an increase in blood flow (Ruane-O'Hora et al., 2019). This indicates that the most abundant glycoproteins of the vascular glycocalyx may not be endothelial-blood flow mechanosensors in conduit vessels, as previously reported (Hecker et al., 1993; Mochizuki et al., 2003; Tarbell, Simon & Curry, 2014). In addition, immunohistochemistry also revealed that removal of heparan sulfate did not affect transmembrane syndecan expression, indicating that syndecans also do not play a part in nitric oxide flow mediated dilation in vivo, confirming data from a recent study

(Bartosch, Mathews & Tarbell, 2017). However, it is possible that flow induced vasodilation was maintained since two constituents were removed separately; or, that the glycocalyx-mechanosensory role is a property of the entire structure and not just one or two of the many elements present.

Therefore, the purpose of the present study was to determine if concomitant removal of both heparan sulfate and hyaluronan enzymatically would affect flow-induced vasodilation. Further, N-Formylmethionine-leucyl-phenylalanine (fMLP) a chemotactic agent that degrades the glycocalyx in its entirety was also used. Finally, the role of glycocalyx-sialic acid residues in flow mediated dilation was also evaluated. All experiments were carried out on an established vascular model using the iliac artery of the anesthetized pig (Markos *et al.*, 2008).

MATERIALS AND METHODS

Methods

Procedures were performed under license in accordance with Irish and European directive 2010/63/EU following approval by University College Cork animal research ethics committee and the Health Products Regulatory Authority (HPRA). Project authorization number: AE19130/P025.

Surgery and instrumentation

A total of 15 female landrace pigs (18.2–34.4 kg) were sedated with ketamine (14 mg kg⁻¹) and xylazine (2.7 mg kg⁻¹) i.m. A cannula was inserted into an ear vein and the animal was anesthetized with sodium pentobarbital (30 mg kg⁻¹ for induction; 6 mg kg⁻¹ h⁻¹ for maintenance i.v.). Anesthetic infusion was maintained via a central line and an infusion pump (Harvard). Vital signs were monitored using SurgiVet Advisor Vital Signs Monitor (Smiths Medical, Dublin, OH, USA). An i-STAT analyzer (Abbot Point of Care Inc., Princeton, NJ, USA) was used to assess pH, P_aCO₂ and P_aO₂ and these parameters were kept within the normal range. A tracheotomy was performed and the pigs animals were ventilated with 40% O₂ in room air using a ventilation pump (Harvard apparatus).

A cannula was inserted into the carotid artery to measure systemic blood pressure (Grass; Grass Technologies, West Warwick, RI, USA). The left or right iliac artery was exposed and instrumented as previously described (Markos *et al.*, 2008; Ruane-O'Hora *et al.*, 2019), shown in Fig. 1. A cannula attached to a 3-way tap was placed in the deep femoral artery for injection of the compounds used to affect the glycocalyx-in-blood into the iliac. Piezoelectric crystals placed on opposite sides of the iliac measured diameter using a UDG sonomicrometer (Sonometrics Corporation, London, ON, Canada). A flow transducer (Transonic Systems Inc., Ithaca, NY, USA) was placed around the iliac for blood flow measurement. When needed, bulldog clips (top and bottom clips in Fig. 1) were placed above and below the diameter measurement site to isolate a test segment of iliac. All signals were recorded using a Power lab (AD Instruments Ltd., Oxford, UK) and a PC. Following experimental procedures animals were killed using a lethal injection of pentobarbitone and KCL i.v.




Figure 1 Schematic diagram showing the experimental preparation. Artists: Therese Ruane-O’Hora & Farouk Markos. [Full-size !\[\]\(ba1b80118482ccef74a5d718ca4d7242_img.jpg\) DOI: 10.7717/peerj.8725/fig-1](https://doi.org/10.7717/peerj.8725/fig-1)

Protocol

Two acetylcholine infusions (5–20 $\mu\text{g}/\text{min}$) downstream of the iliac measurement site were carried out, one before (the control response) and one after a test segment was isolated and injected with arterial blood containing (a) heparinase III (100 mU ml^{-1}) and hyaluronidase (14 $\mu\text{g ml}^{-1}$); (b) neuraminidase (140 mU ml^{-1}); (c) or fMLP (1 μM) for 20 min. An example of records obtained from one experiment (Fig 21/14) is shown in Fig. 2. Only one experimental intervention per iliac was conducted. It is important to note that acetylcholine infusion cannot directly interact with the diameter measurement site since it was infused downstream and also cannot circulate to affect systemic pressure (see Fig. 2) since acetylcholine is rapidly neutralized by blood cholinesterases.

Data analysis

Wall shear stress (N m^{-2}) was calculated from the internal diameter (D), mean blood velocity (V_m) and blood viscosity ($\mu = 4 \text{ mN s m}^{-2}$). Shear stress (S) is given by: $S = 8V_m \cdot \mu \cdot D^{-1}$. Data was analyzed using paired Student’s t test, $P < 0.05$ was considered significant and data is presented as mean \pm s.e.m.

Drugs used

Heparinase III, hyaluronidase, neuraminidase and fMLP were purchased from Sigma, anesthetics were purchased from Abbeyville Veterinary Hospital, Togher, Cork.




Figure 2 Records from pig Pig 21/14 showing a control flow mediated dilation of the iliac from a downstream infusion of acetylcholine ($20 \mu\text{g}/\text{min}$). The infusion was switched off soon after the peak diameter response, there was no effect of acetylcholine on systemic blood pressure (measured in the carotid) or heart rate. [Full-size](#) DOI: 10.7717/peerj.8725/fig-2

RESULTS

Baseline cardiovascular parameters at the onset of recording were as follows, heart rate averaged $111 \pm 9 \text{ beats min}^{-1}$ (range $55\text{--}197 \text{ beats min}^{-1}$), mean arterial blood pressure was $75 \pm 4 \text{ mm Hg}$ (range $56\text{--}101 \text{ mm Hg}$), mean iliac blood flow was $120 \pm 13 \text{ ml min}^{-1}$ (range $58\text{--}220 \text{ ml min}^{-1}$) and internal iliac diameter was $2 \pm 0.012 \text{ mm}$ (range $1.4\text{--}2.76 \text{ mm}$).

In Fig. 2, an example of records from one shows the effect of acetylcholine infusion downstream of the iliac diameter measurement site. The iliac test segment dilates in response to the increase in blood flow with little to no change in blood pressure or heart rate; since acetylcholine can only act in the vicinity and cannot re-circulate due to blood cholinesterases. This same protocol was repeated after the iliac segment was exposed to enzymes or fMLP.

Heparinase III (100 mU ml^{-1}) and hyaluronidase ($14 \mu\text{g ml}^{-1}$)

Four pigs were used in this series of experiments and the data obtained is summarized in Fig. 3. Treatment of the iliac lumen for 20 min using both enzymes to selectively remove the heparan sulfate and hyaluronic acid components of the glycocalyx did not significantly reduce flow mediated iliac dilation, which increased by an average of $0.54 \pm 0.11 \text{ mm}$ before and $0.45 \pm 0.03 \text{ mm}$ after the enzymes ($P = 0.42$) for a statistically similar increase in shear stress; $15.4 \pm 2.6 \text{ N m}^{-2}$ for the control and $10.2 \pm 1.4 \text{ N m}^{-2}$ for the heparinase III + hyaluronidase experiment ($P = 0.15$).

fMLP ($1 \mu\text{M}$)

Six pigs were used and the data obtained is summarized in Fig. 4. Treatment of the iliac lumen for 20 min using the chemotactic agent fMLP to remove the entire glycocalyx also




Figure 3 Concomitant application of both heparinase III and hyaluronidase did not cause a significant reduction in flow mediated dilation ($n = 4$ pigs).

Full-size DOI: 10.7717/peerj.8725/fig-3

did not significantly reduce flow mediated dilation, diameter increased by 0.31 ± 0.02 mm before and 0.29 ± 0.07 mm after fMLP exposure ($P = 0.7$) for a statistically similar increase in shear stress; 17.7 ± 3.5 N m⁻² for the control and 15.6 ± 4.5 N m⁻² for the fMLP experiment ($P = 0.68$).

Neuraminidase (140 mU ml⁻¹)

Five pigs were used in this series of experiments and the data obtained is summarized in Fig. 5. Exposure of the iliac lumen for 20 min to neuraminidase to remove the sialic acid component of the glycocalyx did not significantly affect flow mediated dilation, diameter increased by 0.54 ± 0.11 mm before and 0.54 ± 0.09 mm after neuraminidase exposure ($P = 0.98$) for a statistically similar increase in shear stress; 18.3 ± 3.8 N m⁻² for the control and 20.6 ± 5 N m⁻² for the neuraminidase experiment ($P = 0.6$).

DISCUSSION

The main finding of the current study is that the entire glycocalyx structure in a conduit artery is not required to cause an increase diameter in response to an increase in blood flow, confirming and extending the conclusions of a recent article (Ruane-O'Hara *et al.*, 2019). With regard to the effectiveness of the various compounds used to degrade the glycocalyx, Gao & Lipowsky (2010) previously showed that administration of a combination of enzymes caused much greater glycocalyx damage (reduction in thickness) than individual enzyme application. The concentration of enzymes used and the duration




Figure 4 Application of fMLP to damage the entire glycocalyx in the iliac artery did not cause a significant reduction in flow mediated dilation ($n = 6$ pigs).

Full-size DOI: 10.7717/peerj.8725/fig-4




Figure 5 Removal of glycocalyx sialic acid residues using the enzyme neuraminidase did not cause a significant reduction in flow mediated dilation ($n = 5$ pigs).

Full-size DOI: 10.7717/peerj.8725/fig-5

of exposure in the artery lumen was comparable to previous studies and was known to significantly reduce expression of both heparan sulfate and hyaluronic acid (*Chappell et al., 2008; Florian et al., 2003; Ruane-O'Hora et al., 2019*). The results post-neuraminidase treatment also show that sialic acid residues do not act as mediators of shear stress in vivo, which is at odds with findings from studies carried out in isolated artificially perfused arteries (*Hecker et al., 1993; Kumagai, Lu & Kassab, 2009; Pohl et al., 1991*).

fMLP, a known chemoattractant and inflammatory agent, was used to cause diffuse glycocalyx damage. While we do not have visual images to show degradation of the glycocalyx in response to fMLP in the present study, a previous investigation carried out in situ on exteriorized rat mesentery post capillary venules demonstrated a very rapid loss of glycocalyx after only 10 min (*Mulivor & Lipowsky, 2004*). Again, flow mediated dilation was not significantly affected following treatment of the artery lumen with fMLP. It should be noted that there is in vitro evidence that heparan sulfate bound glypican is involved in nitric oxide flow-mediated mechanotransduction (*Ebong et al., 2014*). Whether fMLP removed the glypicans together with the associated heparan sulfate is not clear.

There is obvious conflict between our data obtained in vivo and virtually all other studies in this field, which are conducted using either cultured cells or excised arteries perfused with physiological solutions. However, ex-vivo preparations are known to quickly lose glycocalyx components (*Chappell et al., 2008*), and cultured endothelial cells only express a rudimentary and incomplete glycocalyx (*Chappell et al., 2008; Potter & Damiano, 2008*). It is likely that glycocalyx-vascular function is artery specific, since glycocalyx damage in resistance arterioles due to maintained exposure to either hyaluronidase or fMLP causes a small but significant reduction in arterial conductance (*Ruane-O'Hora & Markos, 2018*).

CONCLUSIONS

Overall, the findings support the importance of whole animal in vivo experiments and while conduit artery dilation is dependent on an intact endothelium it does not require a complete glycocalyx.

ADDITIONAL INFORMATION AND DECLARATIONS

Funding

This study was funded by the Department of Physiology UCC. The SurgiVet Monitor was purchased with a grant from the Strategic Research Fund UCC 2012. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Grant Disclosures

The following grant information was disclosed by the authors:
Department of Physiology UCC.

Competing Interests

The authors declare that they have no competing interests.

Author Contributions

- Therese Ruane-O’Hora conceived and designed the experiments, performed the experiments, analyzed the data, prepared figures and/or tables, authored or reviewed drafts of the paper, and approved the final draft.
- Ahmad Ahmeda analyzed the data, authored or reviewed drafts of the paper, and approved the final draft.
- Farouk Markos conceived and designed the experiments, performed the experiments, analyzed the data, prepared figures and/or tables, authored or reviewed drafts of the paper, and approved the final draft.

Animal Ethics

The following information was supplied relating to ethical approvals (i.e., approving body and any reference numbers):

Procedures were performed under license in accordance with Irish and European directive 2010/63/EU following approval by the University College Cork Animal Research Ethics Committee and the Health Products Regulatory Authority (HPRA) (project authorization number: AE19130-P025).

Data Availability

The following information was supplied regarding data availability:

The raw data is available in the [Supplemental File](#).

Supplemental Information

Supplemental information for this article can be found online at <http://dx.doi.org/10.7717/peerj.8725#supplemental-information>.

REFERENCES

- Bartosch AMW, Mathews R, Tarbell JM. 2017.** Endothelial glycocalyx-mediated nitric oxide production in response to selective AFM pulling. *Biophysical Journal* **113**(1):101–108 DOI [10.1016/j.bpj.2017.05.033](https://doi.org/10.1016/j.bpj.2017.05.033).
- Chappell D, Jacob M, Rehm M, Stoeckelhuber M, Welsch U, Conzen P, Becker BF. 2008.** Heparinase selectively sheds heparan sulphate from the endothelial glycocalyx. *Biological Chemistry* **389**(1):79–82 DOI [10.1515/BC.2008.005](https://doi.org/10.1515/BC.2008.005).
- Ebong EE, Lopez-Quintero SV, Rizzo V, Spray DC, Tarbell JM. 2014.** Shear-induced endothelial NOS activation and remodeling via heparan sulfate, glypican-1, and syndecan-1. *Integrative Biology* **6**(3):338–347 DOI [10.1039/C3IB40199E](https://doi.org/10.1039/C3IB40199E).
- Florian JA, Kosky JR, Ainslie K, Pang Z, Dull RO, Tarbell JM. 2003.** Heparan sulfate proteoglycan is a mechanosensor on endothelial cells. *Circulation Research* **93**(10):e136–e142 DOI [10.1161/01.RES.0000101744.47866.D5](https://doi.org/10.1161/01.RES.0000101744.47866.D5).
- Gao L, Lipowsky HH. 2010.** Composition of the endothelial glycocalyx and its relation to its thickness and diffusion of small solutes. *Microvascular Research* **80**(3):394–401 DOI [10.1016/j.mvr.2010.06.005](https://doi.org/10.1016/j.mvr.2010.06.005).

- Hecker M, Mülsch A, Bassenge E, Busse R. 1993.** Vasoconstriction and increased flow: two principal mechanisms of shear stress-dependent endothelial autacoid release. *American Journal of Physiology* **265**:H828–H833.
- Kumagai R, Lu X, Kassab GS. 2009.** Role of glycocalyx in flow-induced production of nitric oxide and reactive oxygen species. *Free Radical Biology and Medicine* **47**(5):600–607
DOI [10.1016/j.freeradbiomed.2009.05.034](https://doi.org/10.1016/j.freeradbiomed.2009.05.034).
- Markos F, Ruane-O’Hora T, Snow HM, Kelly R, Wainwright C, Skene K, Drake-Holland AJ, Noble MI. 2008.** Dilatation in the femoral vascular bed does not cause retrograde relaxation of the iliac artery in the anaesthetized pig. *Acta Physiologica* **194**(3):207–213
DOI [10.1111/j.1748-1716.2008.01882.x](https://doi.org/10.1111/j.1748-1716.2008.01882.x).
- Mochizuki S, Vink H, Hiramatsu O, Kajita T, Shigeto F, Spaan JA, Kajiya F. 2003.** Role of hyaluronic acid glycosaminoglycans in shear-induced endothelium-derived nitric oxide release. *American Journal of Physiology-Heart and Circulatory Physiology* **285**(2):H722–H726
DOI [10.1152/ajpheart.00691.2002](https://doi.org/10.1152/ajpheart.00691.2002).
- Mulivor AW, Lipowsky HH. 2004.** Inflammation- and ischemia-induced shedding of venular glycocalyx. *American Journal of Physiology-Heart and Circulatory Physiology* **286**(5):H1672–H1680 DOI [10.1152/ajpheart.00832.2003](https://doi.org/10.1152/ajpheart.00832.2003).
- Pohl U, Herlan K, Huang A, Bassenge E. 1991.** EDRF-mediated shear-induced dilation opposes myogenic vasoconstriction in small rabbit arteries. *American Journal of Physiology* **261**:H2016–H2023.
- Potter DR, Damiano ER. 2008.** The hydrodynamically relevant endothelial cell glycocalyx observed in vivo is absent in vitro. *Circulation Research* **102**(7):770–776
DOI [10.1161/CIRCRESAHA.107.160226](https://doi.org/10.1161/CIRCRESAHA.107.160226).
- Ruane-O’Hora T, Markos F. 2018.** The arteriolar glycocalyx plays a role in the regulation of blood flow in the iliac of the anaesthetised pig. *Physiological Research* **67**:41–44
DOI [10.33549/physiolres.933630](https://doi.org/10.33549/physiolres.933630).
- Ruane-O’Hora T, O’Malley D, Buckley MM, Markos F. 2019.** Heparan sulphate and hylauronic acid components of the glycocalyx do not play a role in flow mediated dilation of the iliac in the anaesthetized pig. *Canadian Journal of Physiology and Pharmacology* **97**(8):746–752
DOI [10.1139/cjpp-2019-0124](https://doi.org/10.1139/cjpp-2019-0124).
- Tarbell JM, Simon SI, Curry FR. 2014.** Mechanosensing at the vascular interface. *Annual Review of Biomedical Engineering* **16**(1):505–532 DOI [10.1146/annurev-bioeng-071813-104908](https://doi.org/10.1146/annurev-bioeng-071813-104908).